DYAI Stock Analysis: Buy, Sell, or Hold?
DYAI - Dyadic International, Inc.
$0.72
0.03 (4.64%)
▲
5d:
-5.81%
30d:
-17.67%
90d:
-13.01%
HOLD
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 20, 2026
3d
Get Alerted When DYAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called DYAI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DYAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DYAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: DYAI is currently trading at $0.72, which is considered oversold relative to its 30-day fair value range of $0.75 to $0.87. From a valuation perspective, the stock is trading at a discount (Forward PE: -9.6) compared to its historical average (81.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DYAI is in a downtrend. Immediate support is located at $0.68, while resistance sits at $0.79. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: DYAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.00 (+869.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DYAI is in a downtrend. Immediate support is located at $0.68, while resistance sits at $0.79. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: DYAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.00 (+869.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.75 -
$0.87
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 869.5% below Wall St target ($7.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.75 -
$0.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.79
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.63
Wall Street Target
$7.00
(+869.5%)
Revenue Growth (YoY)
182.3%
Profit Margin
-191.5%
PE vs Historical
-9.6 vs 81.5
CHEAP
Share & Embed Analysis
Last updated: May 16, 2026 6:07 AM ET
Data refreshes hourly during market hours. Next update: 7:07 AM
Data refreshes hourly during market hours. Next update: 7:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 53 HOLD |
